The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the national lipid association and the American society for preventive cardiology

Elsevier

Available online 27 February 2023

Journal of Clinical LipidologyAuthor links open overlay panel, , , , , , , , , , Highlights•

National metrics do not include LDL-C measurement as a necessary performance metric.

This clinical perspective reviews history of LDL-C as a quality/performance metric.

Lipid monitoring is essential for assessing lipid-lowering pharmacotherapy.

Evidence favors LDL-C measurement to improve population-wide lipid control.

Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the leading cause of morbidity and mortality in the United States, national quality assurance metrics no longer include LDL-C measurement as a required performance metric. This clinical perspective reviews the history of LDL-C as a quality and performance metric and the events that led to its replacement. It also presents patient, healthcare provider, and health system rationales for re-establishing LDL-C measurement as a performance measure to improve cholesterol control in high-risk groups and to stem the rising tide of CVD morbidity and mortality, cardiovascular care disparities, and related healthcare costs.

Keywords

Cardiovascular disease

LDL Cholesterol

Risk factors

Blood pressure

Lipoprotein modifying

Statins

© 2023 Published by Elsevier Inc. on behalf of National Lipid Association.

留言 (0)

沒有登入
gif